Annual Report 2025

CHAIRMAN’S STATEMENT 6 The United Laboratories International Holdings Limited Annual Report 2025 Dear Shareholders, In 2025, the external environment remained complex and volatile. Guided by a high-quality development strategy, China’s economy maintained steady progress with improvements in both quantity and quality. The past year marked the conclusion of China’s 14th Five- Year Plan. The pharmaceutical industry continued to see policy refinements, with the combined effects of measures such as the normalisation of centralised procurement, the full implementation of reformed medical insurance payment methods, and the accelerated review and approval process for innovative drugs becoming evident, driving the industry’s accelerated transformation and upgrading. Since the inception of the 14th Five-Year Plan, China’s pharmaceutical sector has achieved significant accomplishments in areas including innovative drugs, high-end manufacturing, industrial scale, and internationalisation, consistently achieving leapfrog development driven by innovation and laying a solid foundation for the “Healthy China” initiative and global pharmaceutical competition. Facing the opportunities and challenges presented by this new landscape, the Group has maintained a clear strategic focus, seizing the initiative amidst change and seeking breakthroughs amidst challenges. By focusing on R&D innovation and deepening our global footprint, we have cemented a solid foundation for the Group’s long-term sustainable development. On behalf of the board of Directors (the “Board”) of The United Laboratories International Holdings Limited (the “Company” or “The United Laboratories”), I am pleased to present to our shareholders and partners the annual results of the Company and its subsidiaries (the “Group”) for the year ended 31 December 2025 (the “Year”). Mr. Tsoi Hoi Shan Chairman